Actively Recruiting
A Biospecimen Collection Study of Leukapheresis-Derived Circulating Tumor Cells, Immune Cells, and Progenitor Cells.
Led by BioCytics, Inc. · Updated on 2026-03-18
1500
Participants Needed
1
Research Sites
1161 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Primary Objective: This is a study to investigate the feasibility of harvesting, expanding, and selecting T lymphocytes from cancer patients and healthy volunteers. The preliminary objective of this study is aimed at selecting PD-1+ and CTLA4+ T cells and other cellular fractions from peripheral blood of cancer patients and healthy volunteers by using specific conjugated antibodies, evaluating their functional ex vivo anti-tumor cytotoxicity against targeted autologous tumor cells.
CONDITIONS
Official Title
A Biospecimen Collection Study of Leukapheresis-Derived Circulating Tumor Cells, Immune Cells, and Progenitor Cells.
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Adults 18 years or older with any type or stage of solid tumor
- Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 to 3 and life expectancy of at least 3 months
- Written informed consent provided by participant or legal representative
- Negative test results for HIV, Hepatitis B surface antigen, and Hepatitis C antibody, or negative PCR test results for these viruses
- For leukapheresis: ECOG status 0 or 1; certain minimum blood counts and organ function levels; negative pregnancy test for women of childbearing potential
- Healthy adults 18 years or older, including those with stable autoimmune or inflammatory diseases, and those with suspected or confirmed COVID-19
- Pediatric healthy volunteers aged 5 to 17 years with suspected or confirmed COVID-19 may participate in minimally invasive sample collections with parental consent and child assent if applicable
You will not qualify if you...
- Active infection requiring therapy, including acute or sub-acute COVID-19 infection
- Medical conditions that may affect safety interpretation as judged by the investigator
- Positive PCR test for HIV, Hepatitis B Virus, or Hepatitis C Virus
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Carolina BioOncology Institute
Huntersville, North Carolina, United States, 28078
Actively Recruiting
Research Team
J
John Powderly, MD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
3
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here